Clinical Trial Update: Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ARC1779 for thrombotic microangiopathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy
• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• ARC1779

Snippet

Sponsor: Archemix Corp. | Conditions: Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: TERMINATED